Redcare Pharmacy stock slips as Q3 Rx growth keeps targets intact
Published on 11/04/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- German prescription sales remained Redcare Pharmacy's main growth engine in the third quarter.
- Profitability improved for a second consecutive quarter, while management kept its upgraded outlook.
- The next scheduled company update is the 2026 trading statement on January 11, 2027.
Redcare Pharmacy reported stronger third-quarter growth on October 29, led by German prescription sales and accompanied by a second consecutive quarterly profit. The latest quote put the stock at 72.78 euros on Lang & Schwarz at 18:13 CET on Wednesday, November 4, 0.11 percent above the Xetra close of 72.70 euros from Wednesday. That was 1.85 percent below the 74.15 euros quoted in our November 3 report at 18:38 CET.
Prescription sales lead growth
According to the EQS News release carried by AD HOC NEWS, group revenue increased 18 percent year over year to 847 million euros in the third quarter. Prescription revenue grew 31 percent to 358 million euros, with German prescription revenue advancing 56 percent to 197 million euros. Non-prescription revenue rose 9 percent to 489 million euros.
The active customer base reached 15.2 million at the end of September. Redcare said the total increased by 0.5 million during the quarter, while German prescription activity added 123,000 active customers.
Profitability and targets improve
Adjusted EBITDA rose 68 percent year over year to 28.7 million euros, lifting the margin to 3.4 percent from 2.4 percent. Net income was positive at 1 million euros, and quarterly free cash flow reached 15 million euros.
Management confirmed its upgraded 2026 targets, including total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent. The company expects positive free cash flow in 2027, with its next scheduled trading statement due on January 11, 2027.
The real-time quote of Redcare Pharmacy stock provides the latest trading view.
Redcare Pharmacy at a glance
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC.DE
- Home listing: Frankfurt Stock Exchange, Prime Standard
- Index: SDAX
- Lang & Schwarz price: 72.78 euros at 18:13 CET on November 4, 2026
- Change versus Xetra close: 0.11 percent above the 72.70 euros Xetra close on November 4, 2026
The Dutch market backdrop can be followed through the AEX index.
More news and analyses on Redcare Pharmacy stock are available in the company topic section.
